Update on novel therapeutic agents for cervical cancer (Q37188066)

18 August 2017

1 reference

title

Update on novel therapeutic agents for cervical cancer (English)

1 reference

18 August 2017

main subject

cervix uterine cancer

1 reference

based on heuristic

inferred from title

author name string

Josep Maria del Campo

1

1 reference

18 August 2017

Aleix Prat

2

1 reference

18 August 2017

Antonio Gil-Moreno

3

1 reference

18 August 2017

José Pérez

4

1 reference

18 August 2017

Marta Parera

5

1 reference

18 August 2017

language of work or name

English

0 references

publication date

9 June 2008

1 reference

18 August 2017

1 reference

18 August 2017

volume

110

1 reference

18 August 2017

issue

3 Suppl 2

1 reference

18 August 2017

page(s)

S72-6

1 reference

Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.016

Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.016

A phase II study of gemcitabine and cisplatin in patients with advanced, persistent, or recurrent squamous cell carcinoma of the cervix

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.016

Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.016

7 January 2021

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.016

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.016

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.016

The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.016

EGF-ERBB signalling: towards the systems level

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.016

ERBB receptors and cancer: the complexity of targeted inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.016

Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.016

Synchronous coexpression of epidermal growth factor receptor and cyclooxygenase-2 in carcinomas of the uterine cervix: a potential predictor of poor survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.016

Expression of epidermal growth factor receptor in carcinoma of the cervix

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.016

Clinical implications of the epidermal growth factor receptor in the squamous cell carcinoma of the uterine cervix

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.016

Prognostic value of epidermal growth factor receptor expression in cervical carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.016

Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.016

Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.016

Critical update and emerging trends in epidermal growth factor receptor targeting in cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.016

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.016

Overexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: implications for Cetuximab-mediated therapy in recurrent/metastatic disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.016

A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.016

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.016

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.016

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.016

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.016

HER2 protein (p185(HER2)) is only rarely overexpressed in cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.016

Prognostic significance of the overexpression of c-erbB-2 protein in adenocarcinoma of the uterine cervix

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.016

Correlation of cervical carcinoma c-erb B-2 oncogene with cell proliferation parameters in patients treated with radiation therapy for cervical carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.016

The significance of Erb-b2 immunostaining in cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.016

Abnormal expression of epidermal growth factor receptor and c-erbB2 in squamous cell carcinoma of the cervix: correlation with human papillomavirus and prognosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.016

Correlation between human epidermal growth factor receptor family (EGFR, HER2, HER3, HER4), phosphorylated Akt (P-Akt), and clinical outcomes after radiation therapy in carcinoma of the cervix

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.016

Angiogenesis in cancer and other diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.016

The biology of vascular endothelial growth factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.016

The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.016

Vascular endothelial growth factor: basic science and clinical progress

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.016

Vascular endothelial growth factor and prognosis of cervical carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.016

Vascular endothelial growth factor (VEGF) expression is a prognostic factor for radiotherapy outcome in advanced carcinoma of the cervix

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.016

Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in cervical neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.016

Expression of human papillomavirus type 16 E6 and E7 oncoproteins in primary foreskin keratinocytes is sufficient to alter the expression of angiogenic factors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.016

Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.016

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.016

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.016

Bevacizumab combination therapy in heavily pretreated, recurrent cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.04.016

10.1016/J.YGYNO.2008.04.016

7 January 2021

Identifiers

DOI

1 reference

18 August 2017

1 reference